Citations

Showing 10 of 108104 citations.

Hepatology Highlights
Tomlinson, Jennifer L. , Ahn, Joseph , Povero, Davide , Ramkissoon, Resham­ , Ahn, Joseph C , Tomlinson, Jennifer , Ilyas, Sumera I. , Arab, Juan Pablo

Mayo Clinic

Hepatology | March 15, 2022 | Volume: 75 | Issue: 4 | Pages: 775-776

10.1002/hep.32418 Get It

Hemophagocytic Lymphohistiocytosis in Refractory Celiac Disease Type II Transformed into Enteropathy-Associated T-Cell Lymphoma
Fogwe, Delvise T. , Cho, Janice , Yuan, Ji , Smyrk, Thomas C. , Ji, Yuan , Yuan, Ji , Murray, Joseph A.

Mayo Clinic

Annals of Internal Medicine: Clinical Cases | March 15, 2022 | Volume: 1 | Issue: 1 | Pages: No page available

10.7326/aimcc.2022.0155 Get It

Standardized Evaluation of Small Renal Masses Using the MRI Clear Cell Likelihood Score
Mileto, Achille , Potretzke, Theodora A. , Potretzke, Theodora

Mayo Clinic

Radiology | March 15, 2022 | Volume: 303 | Issue: 3 | Pages: 600-602

10.1148/radiol.220054 | PMID 35289666 Get It

Altered Left Ventricular Geometry Changes the Border Zone Temporal Distribution of Stress in an Experimental Model of Left Ventricular Aneurysm: A Finite Element Model Study
Moustakidis, Pavlos, Maniar, Hersh S., Cupps, Brian P. , Jie, Zheng , Guccione, Julius M. , Sundt, Thoralf M. , Pasque, Michael K., Absi, Tarek

Mayo Clinic

Circulation | March 15, 2022 | Volume: 106 | Issue: 12_suppl_1 | Pages: No page available

10.1161/01.cir.0000032898.55215.0d Get It

Background Left ventricular aneurysm (LVA) is a significant complication of myocardial infarction that may lead to global left ventricular (LV) dysfunction. However, the exact mechanism underlying the abnormal function has not been elucidated. In this study we tested the hypothesis that changes in LV geometry cause both an increase in wall stress and a change in the temporal distribution of stress in the LVA border zone (BZ) during systole. Methods Transmural anteroapical infarcts were created in adult Dorsett sheep (n=8) and were allowed to mature into LVAs for 10 weeks. Animals were imaged subsequently using MRI with simultaneous recording of intraventricular pressures. Cardiac models were constructed from the MRI images at end-diastole, isovolumic systole, peak-systole and end-systole. Two short-axis slices, 1 basal and 1 apical were analyzed. The apical slice included the septal and anterior component of the aneurysm as well as the corresponding BZs and normal myocardium. Regional wall stresses were calculated using finite element analysis and compared with stresses in corresponding regions from normal control sheep (n=7). Results In the LVA group, stress was significantly increased in the BZ at the end-diastolic, isovolumic, peak-systolic, and end-systolic instants ( P <0.001 for all). In addition the temporal distribution of stress was significantly altered with maximum stress occurring at peak instead of isovolumic systole. Conclusions Geometric changes in the LVA hearts increased wall stress and altered its temporal distribution in the BZ region. Correlation of this finding with the corresponding regional blood flow, oxygen consumption, and mechanical systolic performance may help elucidate the mechanism underlying the observed global LV dysfunction.
Trends of Sources of Clinical Research Funding from 1990 to 2020: A Meta-Epidemiological Study
Burciaga-Jimenez, Erick, Solís, Ricardo César , Sáenz-Flores, Melissa , Zuñiga-Hernández, Jorge A , Zambrano-Lucio, Miguel , Rodríguez‐Gutiérrez, René , Zuñiga-Hernandez, Jorge Alberto , Solis-Pacheco, Ricardo Cesar

Mayo Clinic

Journal of Investigative Medicine | March 15, 2022 | Volume: 70 | Issue: 5 | Pages: 1320-1324

10.1136/jim-2021-002044 | PMID 35292507 Get It

Evidence has raised concerns regarding the association between funding sources and doubtful data. Our main outcome was to analyze trends on funding sources in articles published from 1990 to 2020 in the more influential journals of internal and general medicine. In this meta-epidemiological study, we included peer-reviewed studies from the 10 highest impact journals in general and internal medicine published between January 1990 and February 2020 based on published original research according to the 2018 InCites Journal of Citation Reports, these consisted of the following: The New England Journal of Medicine, The Lancet, JAMA, BMJ, JAMA Internal Medicine, Annals of Internal Medicine, PLOS Medicine, Cachexia, BMC Medicine, and Mayo Clinic Proceedings. Two reviewers working in duplicate extracted data regarding year of publication, study design, and sources of funding. In total, 496 articles were found; of these, 311 (62.7%) were observational studies, 167 (33.7%) were experimental, and 16 (3.2%) were secondary analyses. Percentages of grant sources through the years were predominantly from government (60%), industry (23.83%), and non-governmental (16.06%) organizations. The percentage of industry subsidies tended to decrease, but this was not significant in a linear regression model (r=0.02, p≥0.05). Government and non-government funding sources showed a trend to decrease in the same univariate analysis with both significant associations (r=0.21, p ≤0.001 and r=0.10, p≤0.001, respectively). The main funding source in medical research has consistently been government aid. Despite previous reported data, no association was found between the source of funding and statistically significant results favoring study authors’ hypothesis.
Carfilzomib 56 mg/m 2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment
Terpos, Evangelos , Spencer, Andrew , Goldschmidt, Hartmut , Dirnberger, Franziska, DeCosta, Lucy, Yusuf, Akeem , Kumar, Shaji , Terpos, Evangelos , Goldschmidt, Hartmut , Kumar, Shaji K , Weisel, Katja C , Nooka, Ajay K.

Mayo Clinic

Leukemia & Lymphoma | March 15, 2022 | Volume: 63 | Issue: 8 | Pages: 1887-1896

10.1080/10428194.2022.2047962 | PMID 35289710 Get It

Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer
Ahn, Daniel H. , Walden, Daniel , Bekaii‐Saab, Tanios , Bekaii-Saab, Tanios S

Mayo Clinic

Expert Opinion on Investigational Drugs | March 15, 2022 | Volume: 31 | Issue: 5 | Pages: 437-441

10.1080/13543784.2022.2053107 | PMID 35289234 Get It

Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration‐Resistant Prostate Cancer
Gao, Huanyao , Kim, Wootae , Scholz, Jodi A. , Yu, Jia , Qin, Bo , Zhuang, Yongxian , Tan, Winston , Bryce, Alan H. , Weinshilboum, Richard M. , Wang, Liewei , Xie, Fang , Bryce, Alan H , Kim, Wootae , Qin, Sisi , Zhang, Huan , Gu, Yayun , Kalari, Krishna R. , Sinnwell, Jason P. , Xie, Fang , Yin, Ping , Wei, Lixuan , Weinshilboum, Richard M.

Mayo Clinic

Clinical Pharmacology & Therapeutics | March 15, 2022 | Volume: 111 | Issue: 6 | Pages: 1296-1306

10.1002/cpt.2582 | PMID 35288936 Get It

Approximately one‐third of patients with metastatic castration‐resistant prostate cancer (CRPC) exhibited primary abiraterone resistance. To identify alternative treatment for abiraterone nonresponders, we performed drug discovery analyses using the L1000 database using differentially expressed genes identified in tumor biopsies and patient‐derived xenograft (PDX) tumors between abiraterone responders and nonresponders enrolled in PROMOTE trial. This approach identified 3 drugs, including topoisomerase II (TOP2) inhibitor mitoxantrone, CDK4/6 inhibitor palbociclib, and pan‐CDK inhibitor PHA‐793887. These drugs significantly suppressed the growth of abiraterone‐resistant cell lines and PDX models. Moreover, we identified 11 genes targeted by all 3 drugs that were associated with worse outcomes in both the PROMOTE and Stand Up To Cancer cohorts. This 11‐gene panel might also function as biomarkers to select the 3 alternative therapies for this subgroup of patients with CRPC, warranting further clinical investigation.
Neuromotor control associates with muscle weakness observed with McArdle sign of multiple sclerosis
Schilaty, Nathan D. , Savoldi, Filippo , Nasr, Zahra , Weinshenker, Brian G. , Weinshenker, Brian G , Schilaty, Nathan D , Nasr, Zahra

Mayo Clinic

Annals of Clinical and Translational Neurology | March 15, 2022 | Volume: 9 | Issue: 4 | Pages: 515-528

10.1002/acn3.51526 | PMID 35289110 Get It

AbstractObjectiveMultiple Sclerosis (MS) is often accompanied by myelopathy, which may be associated with progressive worsening. A specific finding of MS‐associated myelopathy is McArdle sign, wherein neck flexion is associated with prominent increased limb weakness relative to that detected with neck extension. In this study, we characterized neuromotor control properties of finger extensors in association with the McArdle sign.MethodsA custom‐built device was utilized to monitor torque production of the wrist extensors with simultaneous recording of surface electromyography of the extensor digitorum. The electromyography was decomposed and analyzed via both linear and nominal regressions.ResultsLinear regressions demonstrated a strong difference between groups for MS from healthy controls and other myelopathies for motor unit action potential amplitude and average firing rate (p < 0.001). Further, linear regression demonstrated good correlations of neuromotor variables to mechanical torque output (0.24 ≤ R2 ≤ 0.76). Nominal regression distinguished MS from healthy controls with an AUC of 0.87, specificity of 0.97, and sensitivity of 0.64. Nominal regression of MS from other myelopathies demonstrated an AUC of 0.88, specificity of 0.85, and sensitivity of 0.79.InterpretationThese data demonstrate the neuromotor control factors that largely determine muscle force production change with the observation of McArdle sign; these neuromotor control factors can differentiate MS from both healthy controls and other myelopathy conditions.
Impact of Parental Adverse Childhood Experiences on Offspring Development in Early Head Start: Parental Adversity and Offspring Development
Miccoli, Antonela , Song, Joanne, Romanowicz, Magdalena , Howie, Flora, Simar, Sandy, Lynch, Brian , Lynch, Brian A

Mayo Clinic

Journal of Primary Care & Community Health | March 15, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/21501319221084165 | PMID 35289215 Get It

Adverse childhood experiences (ACEs) are potentially traumatic events that can cause lifelong suffering, with 1 out of 2 children in the United States experiencing at least 1 ACEs. The intergenerational effect of ACEs has been described, but there’s still paucity of knowledge of its impact on child development and behavior in children enrolled in Early Head Start (EHS) home visiting programs. A retrospective observational study was performed with 71 parents and 92 children participating in the EHS Home Visiting Program in Olmsted County from 2014 to 2019. Parents reported their own ACEs using a 10-item questionnaire. Children’s social-emotional status was evaluated with Devereux Early Childhood Assessment Second Edition (DECA) and development was evaluated using the Brigance Early Childhood Screens III. Referrals of children by EHS staff to community agencies were recorded. The association between parental ACEs score, developmental outcomes and referrals was analyzed. Parental ACEs score of 4 or more was associated with failing at least 1 domain on the Brigance screen ( P = .02) especially adaptive/cognitive domain ( P = .05), and increased risk of referral to community resources ( P < .001). However, there was no association between ACEs scores and failing DECA screens. We identified an intergenerational association between parental exposure to ACEs and risk for childhood developmental delay and referrals to community services. Parental adverse childhood experiences (ACEs) have intergenerational effects on offspring. In our study, parental ACEs are associated with offspring developmental delays and referral to community resources. Screening for parental adverse childhood experiences, a key social determinant of health, is imperative and should be incorporated into primary care and early childhood settings to identify children at risk for developmental delay.